173 related articles for article (PubMed ID: 18981157)
1. Oncostatin M-induced and constitutive activation of the JAK2/STAT5/CIS pathway suppresses CCL1, but not CCL7 and CCL8, chemokine expression.
Hintzen C; Haan C; Tuckermann JP; Heinrich PC; Hermanns HM
J Immunol; 2008 Nov; 181(10):7341-9. PubMed ID: 18981157
[TBL] [Abstract][Full Text] [Related]
2. Peroxiredoxin V selectively regulates IL-6 production by modulating the Jak2-Stat5 pathway.
Choi HI; Chung KJ; Yang HY; Ren L; Sohn S; Kim PR; Kook MS; Choy HE; Lee TH
Free Radic Biol Med; 2013 Dec; 65():270-279. PubMed ID: 23831231
[TBL] [Abstract][Full Text] [Related]
3. Induction of CCL13 expression in synovial fibroblasts highlights a significant role of oncostatin M in rheumatoid arthritis.
Hintzen C; Quaiser S; Pap T; Heinrich PC; Hermanns HM
Arthritis Rheum; 2009 Jul; 60(7):1932-43. PubMed ID: 19565514
[TBL] [Abstract][Full Text] [Related]
4. Phosphorylated CIS suppresses the Epo or JAK2 V617F mutant-triggered cell proliferation through binding to EpoR.
Funakoshi-Tago M; Moriwaki T; Ueda F; Tamura H; Kasahara T; Tago K
Cell Signal; 2017 Feb; 31():41-57. PubMed ID: 28038963
[TBL] [Abstract][Full Text] [Related]
5. Oncostatin M regulates SOCS3 mRNA stability via the MEK-ERK1/2-pathway independent of p38(MAPK)/MK2.
Ehlting C; Böhmer O; Hahnel MJ; Thomas M; Zanger UM; Gaestel M; Knoefel WT; Schulte Am Esch J; Häussinger D; Bode JG
Cell Signal; 2015 Mar; 27(3):555-67. PubMed ID: 25562430
[TBL] [Abstract][Full Text] [Related]
6. Oncostatin M-induced matrix metalloproteinase and tissue inhibitor of metalloproteinase-3 genes expression in chondrocytes requires Janus kinase/STAT signaling pathway.
Li WQ; Dehnade F; Zafarullah M
J Immunol; 2001 Mar; 166(5):3491-8. PubMed ID: 11207308
[TBL] [Abstract][Full Text] [Related]
7. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
Hoermann G; Cerny-Reiterer S; Herrmann H; Blatt K; Bilban M; Gisslinger H; Gisslinger B; Müllauer L; Kralovics R; Mannhalter C; Valent P; Mayerhofer M
FASEB J; 2012 Feb; 26(2):894-906. PubMed ID: 22051730
[TBL] [Abstract][Full Text] [Related]
8. MEK/ERK and signal transducer and activator of transcription signaling pathways modulate oncostatin M-stimulated CCL2 expression in human osteoblasts through a common transcription factor.
Lin SK; Kok SH; Yeh FT; Kuo MY; Lin CC; Wang CC; Goldring SR; Hong CY
Arthritis Rheum; 2004 Mar; 50(3):785-93. PubMed ID: 15022320
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional regulation of the beta-casein gene by cytokines: cross-talk between STAT5 and other signaling molecules.
Chida D; Wakao H; Yoshimura A; Miyajima A
Mol Endocrinol; 1998 Nov; 12(11):1792-806. PubMed ID: 9817603
[TBL] [Abstract][Full Text] [Related]
10. Oncostatin M enhances CCL21 expression by microvascular endothelial cells and increases the efficiency of dendritic cell trafficking to lymph nodes.
Sugaya M; Fang L; Cardones AR; Kakinuma T; Jaber SH; Blauvelt A; Hwang ST
J Immunol; 2006 Dec; 177(11):7665-72. PubMed ID: 17114436
[TBL] [Abstract][Full Text] [Related]
11. Interleukin 9 induces expression of three cytokine signal inhibitors: cytokine-inducible SH2-containing protein, suppressor of cytokine signalling (SOCS)-2 and SOCS-3, but only SOCS-3 overexpression suppresses interleukin 9 signalling.
Lejeune D; Demoulin JB; Renauld JC
Biochem J; 2001 Jan; 353(Pt 1):109-116. PubMed ID: 11115404
[TBL] [Abstract][Full Text] [Related]
12. Deacetylase activity is required for STAT5-dependent GM-CSF functional activity in macrophages and differentiation to dendritic cells.
Sebastián C; Serra M; Yeramian A; Serrat N; Lloberas J; Celada A
J Immunol; 2008 May; 180(9):5898-906. PubMed ID: 18424709
[TBL] [Abstract][Full Text] [Related]
13. Physician Education: The Erythropoietin Receptor and Signal Transduction.
Yoshimura A; Arai K
Oncologist; 1996; 1(5):337-339. PubMed ID: 10388012
[TBL] [Abstract][Full Text] [Related]
14. Mitogen-activated protein kinases Erk1/2 and p38 are required for maximal regulation of TIMP-1 by oncostatin M in murine fibroblasts.
Tong L; Smyth D; Kerr C; Catterall J; Richards CD
Cell Signal; 2004 Oct; 16(10):1123-32. PubMed ID: 15240007
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms.
Gao SM; Chen CQ; Wang LY; Hong LL; Wu JB; Dong PH; Yu FJ
Exp Hematol; 2013 Mar; 41(3):261-70.e4. PubMed ID: 23111066
[TBL] [Abstract][Full Text] [Related]
16. Regulation of IL-17A responses in human airway smooth muscle cells by Oncostatin M.
Kwofie K; Scott M; Rodrigues R; Guerette J; Radford K; Nair P; Richards CD
Respir Res; 2015 Feb; 16(1):14. PubMed ID: 25849622
[TBL] [Abstract][Full Text] [Related]
17. Growth hormone- and prolactin-induced proliferation of insulinoma cells, INS-1, depends on activation of STAT5 (signal transducer and activator of transcription 5).
Friedrichsen BN; Galsgaard ED; Nielsen JH; Møldrup A
Mol Endocrinol; 2001 Jan; 15(1):136-48. PubMed ID: 11145745
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-6 inhibits hepatic growth hormone signaling via upregulation of Cis and Socs-3.
Denson LA; Held MA; Menon RK; Frank SJ; Parlow AF; Arnold DL
Am J Physiol Gastrointest Liver Physiol; 2003 Apr; 284(4):G646-54. PubMed ID: 12519742
[TBL] [Abstract][Full Text] [Related]
19. Interferon-gamma regulates chemokine expression and release in the human mast cell line HMC1: role of nitric oxide.
Gilchrist M; Befus AD
Immunology; 2008 Feb; 123(2):209-17. PubMed ID: 17662042
[TBL] [Abstract][Full Text] [Related]
20. Box 2 region of the oncostatin M receptor determines specificity for recruitment of Janus kinases and STAT5 activation.
Hintzen C; Evers C; Lippok BE; Volkmer R; Heinrich PC; Radtke S; Hermanns HM
J Biol Chem; 2008 Jul; 283(28):19465-77. PubMed ID: 18430728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
